SOM3355 Emerging Drug Insight and Market Forecast - 2032

“SOM3355 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about SOM3355 for Huntington's disease in the 7MM. A detailed picture of the SOM3355 for Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the SOM3355 for Huntington's disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SOM3355 market forecast, analysis for Huntington's disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington's disease.

Drug Summary

SOM3355 is an oral VMAT2 inhibitor (vesicular monoamine transporter 2) for the symptomatic treatment of chorea movements associated with Huntington's disease (HD). SOM3355 has successfully completed Phase IIa trials in Huntington's disease and has shown a favorable safety profile with no depression effects. The program received positive Pre-IND and SA results from the FDA and EMA.

It is a repurposed treatment, meaning that SOM Biotech based its formulation on tetrabenazine, another VMAT2 inhibitor approved to treat Huntington's disease, and tested a library of related compounds until company researchers found a molecule that targets the same receptor. SOM3355 is thought to reduce chorea by inhibiting (blocking) VMAT2 by a mechanism similar to that of tetrabenazine. However, SOM Biotech indicates that the molecule's chemical structure differs considerably from its reference compound.

The company has completed a Phase IIa (NCT03575676) clinical trial to evaluate the safety and efficacy of SOM3355 in chorea movements associated with HD and is currently evaluating a Phase IIb (NCT05475483) study of SOM3355 in patients suffering from Huntington's disease with Choreic movements.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SOM3355 description, mechanism of action, dosage and administration, research and development activities in Huntington's disease.
• Elaborated details on SOM3355 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SOM3355 research and development activity in Huntington's disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SOM3355 (Deutetrabenazine).
• The report contains forecasted sales of SOM3355 for Huntington's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington's disease.
• The report also features the SWOT analysis with analyst views for SOM3355 in Huntington's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SOM3355 Analytical Perspective

In-depth SOM3355 Market Assessment

This report provides a detailed market assessment of SOM3355 in Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

SOM3355 Clinical Assessment

The report provides the clinical trials information of SOM3355 in Huntington's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Huntington's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SOM3355 dominance.
• Other emerging products for Huntington's disease are expected to give tough market competition to SOM3355 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SOM3355 in Huntington's disease.
• This in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SOM3355 in Huntington's disease.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of SOM3355?
• What is the clinical trial status of the study related to SOM3355 in Huntington's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SOM3355 development?
• What are the key designations that have been granted to SOM3355 for Huntington's disease?
• What is the forecasted market scenario of SOM3355 for Huntington's disease?
• What are the forecasted sales of SOM3355 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Huntington's disease and how are they giving competition to SOM3355 for Huntington's disease?
• Which are the late-stage emerging therapies under development for the treatment of Huntington's disease?

This product will be delivered within 2 business days.